Have you purchased yours? Buy Your All-Access Pass now & get lifetime access to all replays and slides! (Lock in the lowest price today)
Geri Brewster- moderator will make opening remarks regarding the known risk factors and environmental triggers for Type 1 DM and Type 1.5 DM specifying environmental and genetic risk factors, as well as glucokinase deficiency MODY 2 (maturity onset diabetes of the young) often requiring insulin for treatment.
Introduction of the panel:
During the panel discussion, moderator Geri Brewster will offer certain concepts for management of optimal blood sugar regulation, including glucose monitoring, pairing proteins and fats with carbohydrates, and a discussion on the modified Atkins diet for consideration of type one individuals with seizure disorders.
Dr. Stephanie Senoff will discuss the major role of glyphosate in the interactome of cystic fibrosis, celiac disease, diabetes and autism.
Dr. Marco Ruggiero will discuss gastrointestinal microbiome influences on autism and autoimmune conditions, with an emphasis on GcMaF.
Dr. Judy Mikovits will present case reports from vaccine court of biological theories of causation of Type 1 DM stemming from vaccine injury. Susceptibility and molecular biomarkers will be presented to prevent disease progression and restore pathways to homeostasis.
Dr. Richard Deth will discuss A1-beta casein and its relationship to type 1 diabetes and the comparison of exposure to it in early childhood versus human milk that contains only A2 beta casein. Epigenetic imprinting and immune and metabolic lifelong consequences will be presented.
Dr. Arthur Krigsman will present on early gastrointestinal insults that shape immune/autoimmune responses.
Each panelist and moderator will have 10 minutes to speak, and additional time with be utilized for audience Q&A.
Marco Ruggiero, MD, PhD
TOPIC: The microbiome in autism spectrum disorders and type 1 diabetes; strategies for nutritional intervention
Type 1 diabetes is recognized as a T-cell-mediated autoimmune process with a strong genetic contribution. An association between autism and a family history of autoimmune disease has been observed since 1971 and a study performed in 2005 demonstrated the prevalence of autism spectrum disorder in children with type 1 diabetes thus suggesting a common autoimmune pathogenesis (Diabetes Care 2005. 28: 925-926). Recent research suggests that such a common autoimmune pathogenesis consists in alterations of the gut microbiome that are responsible for development and progression of type 1 diabetes (Cell Host & Microbe 2015.17:260-273) and of autism. Consistent with this hypothesis, administration of probiotics (mainly Bifidobacteria, Streptococci and Lactobacilli) appears as the most promising treatment for dysbiosis associated with both conditions (Nutrients 2019. 28;11(3). pii: E521). Here we describe a novel immunotherapeutic approach based on a formula containing probiotics known to be effective in type 1 diabetes and autism as well as on vegetal GcMAF, an immunomodulatory molecule known to ameliorate the symptoms of autism (Autism Insights 2012. 4: 31-38).
Stephanie Seneff, PhD
TOPIC: The Interactome of Cystic Fibrosis, Celiac Disease, Diabetes and Autism: a Major Role for Glyphosate
The prevalence of Celiac disease, diabetes and autism have increased alarmingly over the past two decades, in step with the rise in glyphosate usage on core crops. Type 1 diabetes risk is highly correlated with gluten intolerance. Cystic fibrosis is one of the most common genetic diseases in the population in the United States. Patients with cystic fibrosis have 3- to 8-fold increased risk to Celiac disease compared to the general population, and as many as 35% of adults with cystic fibrosis suffer from diabetes. Many parents of children with autism are finding that gluten elimination from the diet improves behavior of their children. Although autism does not seem to be associated with an increased risk to Celiac disease per se, a disproportionate number of autistic kids test high for gluten antibodies. Mothers with type 1 or type 2 or gestational diabetes are at increased risk to producing an autistic child. In this talk, I will try to make sense out of all of these observational correlations, showing how glyphosate could be playing a causal role in all of these diseases and conditions.
Judy Mikovits, PhD
TOPIC: The correlation of Type 1 diabetes and vaccines
Dr. Mikovits will speak about case reports from vaccine court regarding those who got Type 1 diabetes from vaccines.
Richard Deth, PhD
TOPIC: A1 vs. A2 Milk: A Role in Type 1 / 1.5 / Autoimmune Diabetes
1) Consumption of cow milk with A1-type beta case in leads to lower glutathione (GSH) levels because an opioid peptide (BCM7), released during digestion, inhibits absorption of the sulfur amino acid cysteine.
2) The incidence of Type 1 diabetes is highly correlated with the level of A1 milk consumption, suggesting that autoimmunity toward beta islet cells is increased at lower GSH levels.
3) GSH and cysteine levels influence immune responsiveness by competition for cysteine uptake between inhibitory Treg cells and CD4+ helper T cells, and the pro-inflammatory cytokine TNFalpha inhibits cysteine uptake.
4) Human milk has only A2-type beta casein, while infant formula is predominantly A1-type, reflecting a shift of U.S. dairy herds from A2 to A1-type cows during the latter half of the 20th century.
5) Since epigenetic imprinting in early development can have life-long metabolic consequences, these findings suggest that the A1 milk-derived opioid peptide BCM7 may contribute to the risk of Type 1 and Type 1.5 diabetes via inhibition of cysteine absorption.